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A major factor driving research into the pathophysiology of schizophrenia 
has been responsiveness to antipsychotic (dopamine antagonist) medication. 
Despite this it remains unclear whether there is a detectable disorder of dopamine 
function in patients who develop schizophrenia and if so, how it relates to other 
physiological markers of the condition. One reason why research in this area is 
such a challenge is the confounding effects of antipsychotic treatment. 
 
I carried out a case control study on drug-naïve patients with schizophrenia 
who presented to the university hospital clinic in Tainan, Taiwan. I obtained a 
number of clinical and neurobiological measures, thought to be possible disease 
biomarkers. I assessed patients before they received treatment using the following 
methods: (I) single photon emission computed tomography (SPECT) - [99mTc] 
TRODAT-1 for dopamine transporter (DAT) availability; and (II)  Electro-
encephalograms to test event-related potentials (ERPs). Such measures were also 
obtained on healthy controls and appropriate comparisons made. Clinical state 
was assessed using standard scales. 
 
(I): DAT availability through [99mTc]-TRODAT-1 SPECT was compared 
between 47 drug naïve patients with recent onset schizophrenia and 112 healthy 
controls. I also conducted a random effects meta-analysis of the available 
literature synthesizing the results of six comparable published papers as well as 
my current data. The mean specific striatal binding ratio showed a trend for a 
reduction among the patients compared with controls (estimated difference = 
0.071; 95% CI 20.01, 0.15; P =.08). There was an effect of sex, whereby females 
had a higher ratio of specific striatal binding than males. Age was negatively 
correlated with the ratio of specific striatal binding, both in patients and controls. 
The meta-analysis provided a pooled standardized effect size (Cohen’s d) of -0.07 
(95% CI: -0.31, 0.18; p= 0.60) for the patient versus control comparison in 
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TRODAT binding, with no evidence of heterogeneity between studies or 
publication bias. The findings suggest that striatal dopamine transporter levels are 
not altered in the early stages of schizophrenia before medication is introduced.  
 
(II): ERP differences were explored between 36 drug naïve patients with 
schizophrenia and 138 healthy controls and P300 performance was examined in 
relation to dopamine transporter (DAT) availability. I also conducted a random-
effects meta-analysis of the available literature synthesizing the results of 3 
comparable published articles on drug naïve patients as well as my local study. 
The mean P300 ERP showed no overall significant difference between patients 
and controls in latency or in amplitude. However, there was an increase in P300 
latency with age which was more pronounced in the patient group. No effects of 
DAT availability on P300 latency or amplitude were detected. The meta-analysis 
provided a latency pooled standardized effect size (Cohen’s d) of -0.13 (95% CI -
0.37, 0.12; P = 0.31), and an amplitude pooled standardized effect size (Cohen’s d) 
of 0.48 (95% CI -0.002, 0.97; P=0.05) with patients showing a borderline 
significant reduction. My findings suggest the P300 ERP latency is not altered in 
the early stages of schizophrenia before medication is introduced, and the DAT 
availability does not influence the P300 ERP amplitude or latency. P300 ERP 
amplitude reduction could be an indicator of the progression of illness and 
chronicity.  
 
The importance of taking into account medication effects is emphasized by 
this research as is the value of converging methodologies such as research with 
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Schizophrenia is a debilitating and often chronic disorder affecting about 1% 
of the population and with a typical onset in early adulthood (Bogren et al., 2009; 
Simeone et al., 2015). Current research indicates that the longer it remains 
untreated the worse the prognosis and functional outcomes. The identification and 
treatment of psychosis is vital as it is associated with increased risk of self-harm 
and suicide, significant reductions in life expectancy and social exclusion (Chang 
et al., 2011; Dutta et al., 2012; Lopez-Morinigo et al., 2014; Osborn et al., 2015). 
Antipsychotic medication remains the cornerstone of treatment in schizophrenia 
for both the acute presentation as well as the stabilisation-maintenance phase 
(Saunders et al., 2011; Giannopoulos et al., 2014). Despite the widespread 
availability of effective treatment for schizophrenia, its treatment outcome is 
highly variable. Whether neurobiological markers are useful alongside clinical 
measures in predicting disease outcome is still unknown.   
A major factor driving research into the pathophysiology of schizophrenia has 
been the responsiveness to antipsychotic (dopamine antagonist) medication. 
However, besides its clinical benefits, antipsychotic exposure may precipitate 
progressive neuroanatomical brain changes and also adversely influence neural 
activity in schizophrenia (Lui et al., 2010; Fusar-Poli et al., 2013b). Furthermore, 
brain structural change could also be related to antipsychotic responsiveness 
independently of symptom severity and duration of illness (Hutcheson et al., 
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2013). Despite this it remains unclear whether there is a detectable disorder of 
dopamine (DA) functions in patients who develop the disorder, and if so how it 
relates to other physiological markers of the condition. One reason why research 
in this area is such a challenge is the confounding effects of antipsychotic 
treatment. 
 
A review of dopamine function in schizophrenia  
 
      Central dopaminergic hyperactivity continues to be one of the key hypotheses 
of the pathophysiology of schizophrenia (Seeman et al., 1976; Howes & Kapur, 
2009; Howes & Murray, 2014). Excess transmission at dopamine receptors and 
blockade of these receptors to treat psychosis were the primary focus in initial 
formulations back in the seventies (Matthysse, 1973; Snyder, 1976). Later in the 
1990’s, a modified dopamine hypothesis of schizophrenia was proposed by Davis 
et al. based on findings available at the time (Davis et al., 1991). These included 
dopamine neuron lesions in the prefrontal cortex resulting in increased levels of 
dopamine and dopamine D2 receptor density in the striatum (Pycock et al., 1980). 
Further evidence came from applying dopamine agonists to prefrontal areas and 
how this reduced dopamine metabolite levels in the striatum (Scatton et al., 1982). 
These studies suggested that the pathophysiology of schizophrenia was characterized
 by frontal hypodopaminergia resulting in striatal hyperdopaminergia.  
 
      Davis et al. further hypothesized that negative symptoms of schizophrenia 
resulted from frontal hypodopaminergia, and positive symptoms from striatal 
hyperdopaminergia. Furthermore, some studies also suggested that the attribution 
of salience to reward-predicting stimuli and the computation of prediction errors 
(Robinson & Berridge, 1993; Schultz et al., 1993; Schultz et al., 1997), are 
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indeed impaired in patients with schizophrenia due to functional activation 
potentially associated with striatal dopaminergic signaling, and this impairment 
may contribute to delusion formation (Heinz, 2002; Kapur, 2003).  
 
      As briefly outlined in the introduction of chapter 2, the dopamine hypothesis 
of schizophrenia has been revised as subsequent evidence has been emerging 
(Howes & Murray, 2014). According to Howes et al., the dopamine hypothesis 
was built on the findings that antipsychotics work by blocking dopamine D2/3 
receptors, and some drugs (such as amphetamine etc.) which activate the
dopamine system can induce psychotic symptoms (Abi-Dargham, 2004; Curran et 
al., 2004; Berman et al., 2009; Howes et al., 2009a). However, the alterations in 
D2/3 receptor availability of the dopamine system in schizophrenia are inconsistent 
and small at most, whilst there is no difference versus controls in transporter 
availability (Howes et al., 2012; Chen et al., 2013).  
 
       Moreover, evidence for elevated dopamine synthesis capacity, increased 
dopamine release and greater baseline synaptic dopamine levels in schizophrenia, 
have been found all with large effect sizes (Cohen’s d > 0.8) (Howes et al., 2012). 
Therefore, molecular imaging studies indicate presynaptic dysregulation as the 
major locus of dopamine dysfunction in schizophrenia (Howes et al., 2009a; 
Lyon et al., 2011; Howes et al., 2012). Furthermore, the presynaptic dopamine 
abnormality is not simply a non-specific marker of psychiatric illness, since both 
dopamine synthesis capacity and dopamine release are not elevated in people with 
other common psychiatric disorders (Howes et al., 2007), and it even has 
potential as a diagnostic test for schizophrenia (Bose et al., 2008).  
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      The onset of schizophrenia is frequently preceded by a prodromal phase of 
sub-clinical psychotic symptoms. People who present with “at risk” features have 
increased dopamine synthesis capacity on average (Howes et al., 2009b; Egerton 
et al., 2013), though not all “at risk” individuals are truly prodromal and most of 
them will never develop the disease. Elevated dopamine synthesis capacity is 
specific to those who proceed to develop frank psychosis. This greater dopamine 
synthesis capacity is associated with greater severity of sub-clinical symptoms 
only in those who proceed to develop clinical psychosis (Howes et al., 2011). 
Studies using radiotracers selective for dopamine D2/3 receptors to index 
dopamine release following amphetamine use in patients with schizophrenia also 
indicate that greater dopamine release is associated with greater induction of 
psychotic symptoms, and dopamine release is greater in patients who are acutely 
psychotic than in stable remitted patients (Laruelle et al., 1999). Acute depletion 
of intra-synaptic dopamine resulted in a larger increase in D2/3 receptor 
availability in patients with schizophrenia, and the increased occupancy of D2/3 
receptors by dopamine occurred both in first-episode drug naive patients and in 
previously treated chronic patients experiencing an episode of illness 
exacerbation (Abi-Dargham et al., 2000). In conclusion, a link between greater 
dopamine dysfunction and the development of more severe psychotic symptoms 
is indicated in patients with schizophrenia, and it suggests that the dopamine 
dysfunction is dynamic, increasing with the worsening of the disorder. 
 
The importance of dopamine in cognition 
 
      Patients with schizophrenia show impaired cognitive functions which could 
be induced by an increased dopamine release that causes a catastrophic jump of 
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the dorsolateral prefrontal cortex activity from a low to a high level (Tanaka, 
2006). This finding may account for the dorsolateral prefrontal cortex over-
activation in patients with schizophrenia, and the cortical dopamine D2/3 receptor 
function may be more involved in some cognitive functions (i.e. attention, fluency 
and planning) in patients with schizophrenia than in healthy people according to a 
SPECT imaging study (Fagerlund et al., 2013). Some studies report an inverse 
linear relationship between dopamine activity and word production in patients 
with schizophrenia who were tested prior to and following methylphenidate 
infusion during each phase, at the onset of their first-episode (acute phase) and 
then again after they were clinically stable (stabilization phase) (Szeszko et al., 
1999). Similarly, using PET, Slifstein et al. reported deficits in dopamine release 
capacity in the cortex of patients with schizophrenia (Slifstein et al., 2015). Hence 
the literature shows that changes in brain dopamine levels could influence the 
impairments in cognitive functions described among patients with schizophrenia. 
 
The relationship between dopamine and psychopathology in psychosis 
 
Recent imaging studies have illuminated the relationship between dopamine 
activity in various parts of the brain and psychotic symptoms. According to an 
fMRI study in patients with schizophrenia, brain intrinsic activity is changed in 
the striatum, and this corresponds to disorder states and symptom dimensions. 
The intrinsic activity of the striatum is increased in the dorsal part and correlates 
with positive symptoms such as delusions and hallucinations during an acute 
episode of psychosis according to Sorg et al., 2013. The activity of the ventral 
striatum however was found to be increased and correlated with negative 
symptoms, such as emotional withdrawal and blunted affect, in the same patients 
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when they were re-scanned whilst being in remission about 9 months later (Sorg 
et al., 2013). Alterations in dopamine D2 receptor function in the extra-striatal 
region may underlie the positive symptoms of schizophrenia (Suhara et al., 2002; 
Kessler et al., 2009). Furthermore, patients who had greater symptom reduction 
with antipsychotic treatment experienced more severe positive psychotic 
symptoms during the Amphetamine Challenge Test (ACT) (Pandurangi et al., 
1989), which reinforces the key role of dopamine in the genesis of psychotic 
symptoms.     
 
Sex differences in dopamine neurotransmission  
 
There is lower dopamine D2 receptor affinity in females, which suggests an 
increased endogenous striatal dopamine concentration, that may contribute to the 
differential vulnerability of males and females to psychiatric disorders like 
schizophrenia (Pohjalainen et al., 1998). Sex differences in striatal presynaptic 
dopamine synthesis have been also mentioned; thus healthy women were found to 
have significantly higher striatal 18F-DOPA uptake (Ki values) than healthy men, 
indicating females have a higher striatal presynaptic dopamine synthesis capacity 
than healthy males of similar age. Moreover, there was a negative correlation 
between striatal 18F-DOPA Ki values and age in men but not in women, 
indicating a relative decrease in dopamine activity with age in men but not in 
women (Laakso et al., 2002). However, higher DAT availability was found in 
healthy females than in healthy males via single-photon emission tomography 
imaging with [123I] FP-CIT (Lavalaye et al., 2000). This might counteract the 
difference in dopamine synthesis and thus explain there is no increased risk in 
females. Finally, a similar sex effect was found in patients with schizophrenia 
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(Lavalaye et al., 2001).  
 
Further sex differences in dopamine function have been reported among 
patients with schizophrenia. For example, drug-free male patients showed a 
positive correlation of plasma homovanillic acid, a central dopamine metabolite, 
with negative symptoms while females showed no significant relationship with 
any psychotic symptoms (Zhang et al., 2001a; Zhang et al., 2001b). The 
symptoms of schizophrenia could be influenced by the dopamine D2 receptor 
system, and modulated by estrogens since a negative correlation was found 
between symptoms and plasma estrogen levels (Hafner et al., 1993). Indeed, it 
has been proposed that estrogen treatment might be beneficial for females with 
schizophrenia by way of a direct effect on dopamine and serotonin systems or via 
an indirect prolactin-mediated effect (Kulkarni et al., 2001) .  
 
Dopamine function and ageing 
 
Dopamine D2/3 receptor and DAT availabilities in the striatum have been  
found to decline with age in healthy individuals (Volkow et al., 1994; Volkow et 
al., 1996a; Mozley et al., 1999; Lavalaye et al., 2000; Chen et al., 2005). In 
healthy individuals DAT availability shows an estimated 6.6% decrease per 
decade of life (Volkow et al., 1996a). Some in vivo investigations of ageing 
effects on D2 receptors also have consistently shown age-related decreases in 
striatal D2 receptors binding (Antonini & Leenders, 1993; Antonini et al., 1993; 
Volkow et al., 1996b). However, some investigators suggest that the effects of 
aging on DAT do not appear to be linear. Most effects on DAT availability seem 
to occur during young adulthood before people reach the age of 40. The 
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distribution of ageing effects then appears to remain relatively stable until late in 
life (Mozley et al., 1999). 
Older patients with schizophrenia have a narrower therapeutic window for 
antipsychotic drugs than do younger patients (Uchida et al., 2014), partially due 
to an age related decrease in striatal dopamine D2 binding sites (Antonini & 
Leenders, 1993; Antonini et al., 1993; Ichise et al., 1998). This decrease with age 
in some of the key elements of the dopaminergic system explains in part how 
patients become more sensitive to antipsychotics as they become older, and the 
need to lower antipsychotic doses for older patients with schizophrenia (Uchida et 
al., 2009). 
The effects of ageing on dopamine function are well recognized. In my results 
chapters I have accounted for the effects of ageing and discussed how they could 
influence my findings.  
 
 
(1.1)  Brain Dopamine Imaging using [99mTc]-TRODAT-1  
 
Although it is difficult to measure dopamine levels directly in humans, 
neurochemical imaging techniques such as single photon emission computed 
tomography (SPECT) provide indirect indices of dopamine synthesis and release, 
and putative synaptic dopamine levels (Howes & Kapur, 2009). Synaptic 
dopamine competes with the radio-ligand and leads to a reduction in radiotracer 
binding and this provides an indirect index of released dopamine (Laruelle, 2000).  
Dopamine transporters (DATs) are mainly located in the presynaptic 
membrane on the terminal of the dopaminergic projection and they regulate the 
dopamine level in the synaptic cleft (Nirenberg et al., 1996). Hence DAT 
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dysfunction has been implicated in a number of psychiatric and neurological 
disorders (Bannon, 2005; Lindsey & Gatley, 2006).  
A number of positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) radio-ligands are available for DAT imaging in 
humans (Varrone & Halldin, 2010). Several 99mTc-labeled tropane analogues have 
been synthesized and been evaluated as DAT imaging agents (Kung et al., 1996; 
Meltzer et al., 1997; Booij et al., 1999). Among these, 99mTc-labeled TRODAT-1 
is a selective DAT SPECT imaging agent that binds specifically at the DAT site 
of dopamine neuron terminals in both healthy subjects and patients with 
neuropsychiatric disorders (Marek et al., 1996; Staffen et al., 2000; Huang et al., 
2001; Huang et al., 2003; Huang et al., 2004; Seibyl, 2008). 
In this project, [99mTc]-TRODAT-1 was prepared from a pre-formulated 
lyophilized kit provided by the Institute of Nuclear Energy Research (Lung-Tan, 
Taiwan) (Wey et al., 1998). The kit was reconstituted with 1,110 MBq (30 mCi) 
freshly eluted 99mTc-sodium pertechnetate in 5 mL normal saline solution and 
autoclaved at 121°C for 30 minutes to complete the labelling. After cooling to 
room temperature, [99mTc]-TRODAT-1 with a radiochemical purity of 90% 
(determined by a dual-strip instant thin-layer chromatography method) was 
obtained in a neutral solution (pH 7.0-7.5). The shelf life of the lyophilized kit is 
over 2 months when stored at room temperature (Liao et al., 2001). 
The demonstration of the reproducibility of [99mTc]-TRODAT-1 SPECT 
outcome measurements in humans is critical for clinical applications. A [99mTc]-
TRODAT-1 SPECT study in patients with Parkinson’s disease revealed a good 
test-retest reproducibility in striatum with a mean variability of 10.2% and an 
intra-class correlation coefficient (ICC) of 0.95 (Hwang et al., 2004). Since the 
concentrations of DAT are age-dependent (Mozley et al., 1999), it is critical to 
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establish the test-retest reliability of [99mTc]-TRODAT-1 SPECT for DAT 
concentrations measurement in normal young adults. Indeed, representative test-
retest [99mTc]-TRODAT-1 brain SPECT images in young men showed good 
reproducibility between test and retest. The overall variability and ICC of test-
retest specific uptake ratio (SUR) in caudate, putamen and striatum were 7.32-
9.17% and 0.83-0.96, respectively (Yeh et al., 2012).  
 
Other DAT radiotracers 
 
Although patterns of altered radiotracer uptake are similar among the 
different presynaptic dopaminergic imaging agents, the compounds can evaluate 
different aspects of cellular function and may be used in different ways (Table 1). 
The DAT agents bind to a protein transporter located on the presynaptic 
membrane, providing a measure of transporter density as an indirect measure of 
nerve terminal integrity.  
According to Seibyl, dopaminergic radiotracers differ in important ways 
which dictate their application in clinical and research functions. The key 
differences include the nuclide for PET or SPECT, the pharmacokinetics of brain 
uptake and washout and their selectivity for target sites (Seibyl, 2008). The 
specific PET or SPECT radiotracer use depends on the clinical or research 
question to be addressed by imaging (Laruelle et al., 1994; Seibyl et al., 1997; 
Tsuchida et al., 2004). Logistical factors such as radiotracer availability or the 
time to imaging post injection also guide the radiotracer selection.  
SPECT tracers, including [123I] beta-CIT (also known as RTI-55) (Shaya et 
al., 1992; Seibyl et al., 1997), [123I] IPT (Kung et al., 1995; Malison et al., 1995), 
and [123I] FP-beta-CIT (Neumeyer et al., 1994; Kuikka et al., 1995), have been 
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used in vivo for evaluation and assessment of dopaminergic neuronal function. 
Despite the success of these iodine-123-labeled tracers as SPECT imaging agents, 
a tropane analogue incorporating the radionuclide technetium-99m would be 
more desirable. 99mTc, as an isotope for SPECT imaging, is preferred to other 
nuclides due to greater photon flux per unit of radiation dose delivered to the 
patient. Furthermore, there are several characteristics which make this 
radionuclide very attractive: (1) 99mTc has a convenient 6-hour physical half-life, 
(2) it is inexpensive compared to 123I, since 123I is a cyclotron produced isotope 
(cost about $30/mCi), a similar 99mTc labelled agent (99mTc cost about $0.30/mCi) 
will be highly desirable for routine clinical studies and (3) it is available around 
the clock as a solution of 99mTc pertechnetate (99mTcO4-) in normal saline from a 
commercially available 99Mo/99mTc generator. The advantage of ready availability 
and ease of use with 99mTc agents provide a powerful incentive for their 
development (Kung et al., 1997; Kung, 2001). One of the most attractive 
attributes of [99mTc]-TRODAT-1 as a DAT imaging agent is that it is prepared by 
a kit formulation (Choi et al., 1999).  
The Department of Health in Taiwan approved [99mTc]-TRODAT for clinical 
use in 2005. It remains relatively underutilized due to high costs and extensive 
bureaucratic requirements. However, the ready availability of 99mTc plus the 
convenient kit formulation makes this agent ideally suited as a routine clinical 
procedure for imaging the dopamine transporters in the brain. Hence I chose 










Table 1. Comparison of Presynaptic Markers of Dopaminergic Function 
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Adapted and adjusted from: Seibyl, J. P. Single-photon emission computed tomography 
and positron emission tomography evaluations of patients with central motor disorders. 
Semin Nucl Med 2008 
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18F-DOPA: 6-fluoro-(18F)-L-3, 4-dihydroxyphenylalanine 
123I FP-CIT: Iodine-123 N-(3-flouropropyl)-2beta-carbomethoxy-3beta-(4-
iodophenyl) nortropane (FP- CIT)  
11C-VMAT: vesicular monoamine transporter 
123I β-CIT: Iodine-123 beta-CIT (2beta-carbomethoxy-3beta-(4-iodophenyl) 
tropane) 
99mTc-TRODAT: Technetium-99m TRODAT 






(1.2) Literature Review of the P300 Wave in Schizophrenia Research –  
The P300 as a Neurobiological Marker in Schizophrenia 
 
The P300 event related potential 
 
Electrophysiology, a non-invasive imaging tool with outstanding temporal 
resolution, offers an ideal method to investigate cognitive processes and 
psychopathology in vivo. Event Related Potentials (ERPs) are changes in the 
electroencephalogram (EEG) that are typically observed after a certain stimulus 
or cognitive task is performed (Polich, 1998; Mathalon et al., 2000b; Polich, 2007; 
Sumich et al., 2013). The P300 event-related potential (ERP) in particular, is a 
positive deflection of the electroencephalogram peaking about 300 to 
500 milliseconds after a participant receives an attended unusual or a task-
relevant stimulus. The P300 is elicited by infrequent task-relevant stimuli 
embedded in a series of repeated presentations of a standard stimulus (Polich, 
1998; Duncan et al., 2009). The P300 wave is thought to reflect the cognitive 
process triggered by attending to selected sensory stimuli. It is effectively an EEG 
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correlate of sustained attention and working memory processes (Picton, 1992; 
Polich, 2007).  
       The P300 is one of the best characterised physiological biomarkers in 
neuropsychiatric research. The P300 amplitude is widely interpreted as a 
physiological correlate of cognitive resources allocated to processing the task-
relevant stimulus; in other words, a measure of cortical activation during 
attentional efforts (Curran, 2004; Azizian & Polich, 2007). The P300 latency is 
classically interpreted as a central correlate of reaction time and is thought to 
reflect the speed of neural transmission (Picton, 1992; Polich, 2007). There are 
two major sub-components that have been well investigated. The P300a is 
produced without a task when an infrequent distractor in a series of frequent 
stimuli is presented. It is a related to automatic attention processing and more 
frontally distributed. The P300b is elicited by infrequent and task-relevant target 
stimuli during an oddball paradigm. The P3b is most prominent in parietal regions 
and is thought to reflect the weight of attentional resources allocated to the 
detection of target stimuli (Azizian & Polich, 2007; Onitsuka et al., 2013). 
The P300 signal is generated from the summation of activity from multiple 
brain sources, particularly the various association areas of the cerebral cortex and 
the limbic system (Picton, 1992; Bledowski et al., 2004; Polich, 2007; 
Mangalathu-Arumana et al., 2012). Intracranial recordings have indicated that the 
P300 is a component with multiple generators including the prefrontal, anterior 
cingulate, superior temporal and parietal cortices as well as the hippocampus 
(Halgren et al., 1998; Onitsuka et al., 2013). However, despite a considerable 
body of literature, the neurochemical substrates of the P300 and the specific 
neurotransmitter systems involved in generating this ERP response remain poorly 
understood (Picton, 1992; Frodl-Bauch et al., 1999a; Nieuwenhuis et al., 2005; 
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Polich & Criado, 2006). Studies using multi-modal imaging methods on the same 
study participants are needed to help us to elucidate the nature of cognitive 
deficits and symptoms characterising psychosis and this is one of the objectives of 
this thesis. 
 
P300 impairments in schizophrenia 
 
Extensive research has shown that patients with schizophrenia have P300 
amplitude reductions and latency prolongations compared to healthy controls 
(Frangou et al., 1997; Coburn et al., 1998; Ozgurdal et al., 2008; Shin et al., 2010; 
Jahshan et al., 2013). As briefly mentioned in chapter 3, two independent meta-
analyses have summarized the literature examining the P300 waveform in 
schizophrenia and found large effect sizes for this event related potential. The 
latest of these meta-analyses included over 45 original studies yielding a total 
sample size of more than 1400 patients and more than 1250 controls. From this 
work we know that the pooled standardised effect sizes (measured as Cohen’s d) 
were 0.85 for the P300 amplitude reductions and 0.57 for the P300 latency delays 
in patients with schizophrenia when compared with healthy controls. These are 
respectively large and moderate-large effects and are comparable to some of the 
most robust findings in the neuroimaging and neuropsychological literature in 
schizophrenia (Jeon & Polich, 2003; Bramon et al., 2004b).  
There are however some limitations from the P300 schizophrenia literature. 
There was evidence of publication bias affecting the P300 amplitude and this 
means the true effect size might not be quite as strong as 0.8. There was no 
evidence of publication bias with regards to the moderate-large P300 latency 
deficits (Bramon et al., 2004b).  
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Furthermore, this is a common caveat affecting many neuroimaging studies, 
the majority of EEG/ERP experiments available have been conducted with 
chronic patients treated with a range of antipsychotic, antimanic and other 
psychotropic medications. All these drugs are well known to cross the blood brain 
barrier and to influence the human EEG (Ford et al., 1994a; Mathalon et al., 
2000a; Bramon et al., 2004b; Molina et al., 2004) and constitute plausible 
confounders to the proposed impairments typically attributed to the disease. Of 
course, there have also been a substantial number of EEG studies testing only 
patients who were medication free at the time of EEG recording, however these 
are rarely antipsychotic naïve participants (Bramon et al., 2004b). Indeed, 
although the number of available studies is much smaller, antipsychotic free 
patients with schizophrenia have also been shown to have significantly attenuated 
P300 amplitude and delayed latency on oddball paradigms (Coburn et al., 1998; 
Bramon et al., 2004b). This evidence on medication-free patients offers 
reassurance against the important criticisms of medication confounding. 
A wide range of antipsychotic drugs are licensed to treat schizophrenia and 
their potentially diverse effects on the P300 wave are not well understood. 
Although commonly prescribed antipsychotic drugs such as Olanzapine have 
been found to increase P300 amplitude in some studies (Mathalon et al., 2000a; 
Bramon et al., 2004b; Molina et al., 2004), after treatment the P300 performance 
is generally not restored to normal levels (Ford et al., 1994b; Hirayasu et al., 1998; 
Jeon & Polich, 2003). On the contrary, a single study showed that the 
antipsychotic Sulpiride increased the P300 latency (Takeshita & Ogura, 1994). 
Finally, a recent meta-analysis of P300 changes among more than 500 Chinese 
patients with schizophrenia before and after antipsychotic use showed the 
 27 
antipsychotic treatment is associated with a small but significant increase in the 
amplitude and decrease in the latency of P300 (Su et al., 2012).  
 
The P300 as a putative biomarker of psychosis risk 
 
Compared to controls, a P300 amplitude reduction and latency delay was not 
only noted in patients with schizophrenia but also in their unaffected relatives 
such as siblings or offspring investigated as part of family studies (Ebmeier et al., 
1990; Shajahan et al., 1997; Blackwood et al., 1999; Bramon et al., 2005; 
Ozgurdal et al., 2008; Sumich et al., 2008a; Jahshan et al., 2013). These findings 
lend support to the P300 event-related potential being a potential biomarker of 
genetic predisposition towards developing schizophrenia (Bramon et al., 2005; 
Turetsky et al., 2015). Indeed, there is growing interest in using P300 and other 
similar EEG measures as alternative phenotypes for large multi-centre genetic 
association studies in psychosis (Ranlund et al., 2014; Turetsky et al., 2015; Light 
et al., 2015 ). 
Neurophysiological changes such as the reduction in P300 amplitude have 
also been described in populations at high risk of developing schizophrenia who 
present with “prodromal” symptoms, that is short-lived or sub-clinical psychotic 
experiences (van der Stelt et al., 2005; Bramon et al., 2008; Frommann et al., 
2008; van Tricht et al., 2010). In cross-sectional studies, these P300 amplitude 
deficits ran a progressive course, from the prodromal to the chronic phases of 
schizophrenia (Ozgurdal et al., 2008). However, a more recent longitudinal study 
shows that these impairments remain stable from the “prodrome” sub-clinical 
phase until after a full psychotic episode develops (van Tricht et al., 2011). 
Sensory gating, mismatch negativity (MMN), and P300 have all been 
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demonstrated to be impaired in subjects clinically at risk of developing a 
psychotic disorders. Amongst these EEG measures, the duration of MMN showed 
the largest effect size for a difference between converters and non-converters of 
psychosis in a recent meta-analysis (Bodatsch et al., 2015). In one recent study 
the P300 amplitude in combination with clinical parameters showed promising 
performance as a predictor of which individuals at risk for psychosis are more 
likely to develop the disease (Nieman et al., 2014). Similarly, P300 amplitude and 
latency constitute useful alternative phenotypes (endophenotypes) for genetic 
association studies of psychosis (Turetsky et al., 2015). 
Given the literature reviewed from family studies as well as from other 
populations at increased risk of developing schizophrenia, P300 measures from 
auditory oddball paradigms are thought to be vulnerability indicators for 
schizophrenia. However, the influences of antipsychotics on ERP measures are 
poorly understood and medication confounding in case-control cross sectional 
studies remains a plausible and serious problem. Longitudinal studies are one way 
of clarifying such effects. We therefore set out to do a study with antipsychotic 
naïve patients with schizophrenia and after a pre-treatment baseline assessment 
we are in our fifth year of follow up.  
 
The effects of age on the P300 waveform 
 
P300 amplitude reduction with normal aging has been shown in some studies 
(Picton et al., 1984; Ford & Pfefferbaum, 1991; Polich, 1991; Iragui et al., 1993). 
There is clear evidence that P300 latency decreases during the first years of life 
(Polich et al., 1990; Rozhkov et al., 2009), whereas in older adults the parietal 
P300 latency increases, and the parietal P300 amplitude declines with advancing 
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age (Rossini et al., 2007; Ashford et al., 2011). The P300 follows a specific 
trajectory across the lifespan reflecting brain maturation in childhood and 
adolescence and degenerative effects in older age (van Dinteren et al., 2014; 
Tsolaki et al., 2015).  
As noted, reduction of P300 amplitude has been found to be significant in 
drug-naive and first episode schizophrenia patients (de Wilde et al., 2008), but 
importantly, P300 amplitude negatively correlated with age in schizophrenia 
patients (Wang et al., 2003). Although the prolongation of P300 latency with age 
occurred in both groups, the regression slope for P300 latency with age was 
significantly steeper in patients with schizophrenia than in normal controls (Wang 
et al., 2003).  
  As is the case for most cognitive performance measures (Polich, 2007), the 
P300 waveform is influenced by age. The existing literature shows that the effects 
of ageing are in the same direction as the illness-related effects (P300 amplitude 
reductions and latency delays associated with both ageing and schizophrenia). 
Therefore in my thesis I will examine in detail the potential contribution of ageing 
to any difference in clinical groups.  
 
Sex influences on the P300 response 
 
Significant sex-related differences have been found in the response time on 
the behavioural side (button press speed in response to targets) of the P300 ERP 
among healthy individuals, with males showing faster responses than females 
(Tsolaki et al., 2015). Similarly, the level and location of the maximum current 
intensity of the P300 were also noted to differ between sexes, revealing males had 
larger current intensity than females (Tsolaki et al., 2015). Furthermore, the P300 
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amplitude has also been noticed to be greater in healthy females than in healthy 
males (Schiff et al., 2008).    
In younger control populations, girls showed greater bilateral frontal P300 
amplitudes, approaching the higher values observed in boys during childhood. 
Right frontal P300 amplitude has been found to be negatively associated with 
reaction time in girls after controlling for age (Sumich et al., 2012), that is in line 
with previous studies which suggested females rely more on frontal activations 
than males during cognitive tasks (Christakou et al., 2009). These findings have 
demonstrated sex differences in ERP maturation in line with behavioural and 
neuroimaging studies. Reduced auditory P300 amplitude is one of the most robust 
electrophysiological findings in schizophrenia (Turetsky et al., 2009). Sex 
differences for P300 (i.e. lower amplitude in male patients) appear to be preserved 
in schizophrenia (Sumich et al., 2013). Among patients with schizophrenia, men 
showed lower novelty P300 amplitude than women, and particularly in women 
and over the right hemisphere, novelty P300 amplitude was inversely associated 
with excitement (Sumich et al., 2013). Furthermore, depression in patients with 
schizophrenia was significantly positively associated with early perceptual 
processing in response to novel stimuli in men (parietal N100 amplitude), and 
with a later processing stage (parietal P3b) in women (Sumich et al., 2014).  
Therefore, the existing literature shows that the effects of sex on P300 
amplitude in patients with schizophrenia are comparable to the sex differences 
observed in ERP maturation of healthy individuals. Thus amongst people with 
schizophrenia, the males have lower P300 amplitudes than the females. Therefore, 
in my thesis I intend to examine in detail the potential contribution of sex to any 
difference I observe between the clinical groups.    
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The relationship between P300 and psychopathology 
 
Seve ra l  measu res  o f  s ch i zo typy  have  been  a s soc i a t ed  wi th 
electrophysiological measures of brain function, and further shown to be modified 
by sex. Paranormal ideation (PI) was inversely associated with P300 amplitude at 
right-anterior electrodes in women, and right-anterior P300 amplitude was 
negatively associated with unusual experiences (UEs) only in women. These 
results provide support from electrophysiological measures which were modified 
by sex for the dimension of schizotypy, and lend indirect support to dimensional 
conceptions of psychotic and other mental disorders (Sumich et al., 2008b).  
In terms of the relationship with symptoms, P300 subcomponents are 
affected in a different manner by positive versus negative symptoms in patients 
with schizophrenia (Frodl-Bauch et al., 1999b). The auditory P300 amplitude 
recorded in the left hemisphere has been proposed as a potential state marker to 
reflect the severity of positive symptoms and that these positive symptoms may 
be caused by a possible left-hemisphere deficit in schizophrenia (Higashima et al., 
2003). Auditory P300 amplitudes could track clinical fluctuations and are 
considered a state marker of schizophrenia in some studies. For example P300 
amplitude tracked Brief Psychiatric Rating Scale (BPRS) total scores and positive 
symptom scores over time, with decreasing amplitude during symptom 
exacerbations and increasing amplitude associated with improvements in 
psychopathology (Mathalon et al., 2000a). Given the existing literature mostly on 
treated patients, I will examine the relationship between symptom severity 
(measured by PANSS) and P300 amplitude and latency in my sample of drug 
naïve people with schizophrenia. 
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The P300 response and dopamine function in schizophrenia 
 
Only a handful of studies have attempted to investigate the relationship 
between dopamine function and P300 performance and its resulting implications 
for schizophrenia (Kenemans & Kahkonen, 2011). The interactions of 
dopaminergic with other neurotransmitter pathways constitute a considerable 
challenge for this endeavour (Peters et al., 2004; Ford et al., 2007).  
According to Pogarell et al. (2011), D2/D3 receptor availability positively 
correlates with P300 amplitude and negatively correlates with P300 latency. 
Therefore, central dopaminergic activity might play an important role in the 
generation and modulation of the P300 response (Pogarell et al., 2011). 
Dopamine is thought to be critical for the cognitive response to novelty detection. 
In their experiments with healthy volunteers, Rangel-Gomez et al. (2013) 
manipulated dopamine activity using Apomorphine (a D1/D2 agonist) and 
measured the change in several neurological indices of novelty processing. 
Apomorphine speeded and potentiated the novelty-elicited N2, an ERP 
component thought to index early aspects of novelty detection, and caused novel 
words to be better recalled. Apomorphine also decreased the amplitude of the 
novelty P300a waveform. Thus an increase in D1/D2 receptor activation appears to 
potentiate neural sensitivity to novel stimuli, causing this content to be better 
encoded (Rangel-Gomez et al., 2013).  
A range of neurotransmitter systems are thought to influence the P300 
waveform. Dopamine neurotransmission is thought to be of importance in both 
perceptual processing and motor preparation (Kenemans & Kahkonen, 2011). 
Nieuwenhuis et al. indicated a stimulating contribution of the ascending 
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noradrenergic locus–coeruleus system in generating the P300 response, based on 
their review of both animal and human research (Nieuwenhuis et al., 2005). 
Furthermore, the P300 as the prototypical attentional response to relevant or 
salient stimuli has been found to be impaired not only in schizophrenia, but in a 
range of mental health disorders where catecholaminergic deficits play a role such 
as mood disorders and addictions (Jonkman et al., 2000). 
Further investigation of the interaction between P300 ERP and DAT 
function could help us to understand the dopaminergic pathophysiology of 
schizophrenia and this is one of the aims of my thesis. 
 
 
(1.3)   Aims and Hypotheses 
 
This thesis aims to: 
 
(i) Collect a new sample of drug naïve patients with schizophrenia and  
examine their DAT availability and P300 ERP performance (and other  
psychopathology ratings). 
(ii) Investigate the relationship between DAT availability and P300  
performance in drug-naïve schizophrenia. 
(iii) Examine the published evidence from case control studies and conduct 




The following hypotheses will be tested: 
 
• DAT availability will be reduced in drug naïve patients with schizophrenia 
compared to healthy controls. 
 
• The P300 wave will have reduced amplitude and delayed latency in drug  
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naïve patients with schizophrenia compared to healthy controls. 
 
Chapter 2 of this thesis focuses on the role of DA pre-synaptic regulation. I 
compared DAT availability using [99mTc]-TRODAT-1 SPECT between drug 
naïve patients with recent onset schizophrenia and healthy controls in the largest 
study to date. I then conducted a meta-analysis of all studies that used SPECT 
imaging, including my new data, to compare DAT availability in antipsychotic 
naïve patients with schizophrenia versus controls to determine if there is evidence 
of altered DAT availability.    
Chapter 3 of this thesis explored ERP differences between drug naïve patients 
with schizophrenia and healthy controls to examine if P300 performance is 
related to dopamine transporter (DAT) availability, without the confounding 
effects of medication. This was made possible since a subset of the participants in 
this study volunteered to undergo both single photon emission computed 
tomography (SPECT) with [99mTc]-TRODAT-1 as well as EEG testing. I then 
conducted an up-dated meta-analysis of studies that used P300 ERP, including my 
new data, to compare P300 in antipsychotic naïve patients with schizophrenia 
against controls to determine if there is evidence of altered P300 in drug naïve 
patients with schizophrenia. I predicted that P300 amplitude would positively 
correlate with DAT availability while latency would have a negative correlation 
with DAT availability in patients with schizophrenia (Bramon et al., 2004b; Chen 
et al., 2013).  
 
 35 
   
____________________________________________________________________     
Chapter 2 
Striatal dopamine transporter availability in drug naïve patients with 














































































P300 waveform and dopamine transporter availability: a controlled EEG 




































































































Overall discussion and future directions 
_____________________________________________________________________ 
 
This thesis aims to investigate drug naïve patients with schizophrenia and 
examine their DAT availability using SPECT and their P300 ERP performance. 
My colleagues and I also investigated how DAT availability and P300 measures 
related to their psychopathology ratings. We explored the relationship between 
DAT availability and P300 performance. In the thesis I presented our group’s 
own novel data and I conducted meta-analyses of DAT availability and P300 
performance of all available literature. 
 
 
(4.1)    Summary of Thesis Findings  
 
My findings show that the specific striatal binding ratio of drug naïve patients 
with schizophrenia was not significantly different to that of normal controls, 
indicating that both groups had similar dopamine transporter (DAT) availability. 
My DAT study is the largest to date, including over twice the sample of drug 
naïve/drug free patients of the next largest study of DAT in schizophrenia 
(Laruelle et al., 2000). Another strength of my study is that all the subjects were 
drug-naïve, and at a uniform and early stage of their illness. My findings are 
consistent with previous SPECT studies of schizophrenia using [99mTc]-
TRODAT-1, which were included in my meta-analysis (Hsiao et al., 2003; Yang 
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et al., 2004; Schmitt et al., 2005; Schmitt et al., 2006; Schmitt et al., 2008; Chou, 
2010). 
The DAT meta-analysis including my data found there was no evidence for a 
difference in striatal [99mTc]-TRODAT-1 binding in drug-naïve patients with 
schizophrenia compared to controls. Considering the range of effect sizes 
included in the 95% confidence interval, the standardized effect size is unlikely to 
exceed 0.31, which is conventionally considered to be a small effect (Cohen, 
1988).  
 
My other findings show that drug naïve patients with schizophrenia did not 
differ significantly from healthy controls in amplitude or latency of the P300 ERP. 
Furthermore, in my sample I found no evidence that DAT availability influences 
P300 amplitude or latency.  
The main strengths of my P300 ERP study are again that I recruited a large 
and clinically homogenous sample, all the subjects were drug naive and patients 
were at a uniform and early stage of their illness. Thus compared to most previous 
studies, mine can avoid the confounding effects of medication and chronicity of 
illness. 
The P300 meta-analysis including my data found that, drug-naive patients 
with schizophrenia do not have significant impairments in P300 latency compared 
with controls. Considering the pooled effect size of -0.13 and the range of effect 
sizes included in the 95% CI, the standardized effect size is unlikely to exceed -
0.37, which is conventionally considered to be a moderate effect (Cohen, 1988). 
The meta-analysis of P300 amplitude yielded a much larger pooled standardized 
effect size of 0.48 with patients showing a trend for significance in amplitude 
reductions (Cohen, 1988). 
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(4.2)    DAT Availability: Methodological Considerations 
 
It is important to consider the possible influence of tobacco smoking since a 
decrease in DAT availability in the striatum of smokers has been described in 
previous studies (Newberg et al., 2007). A study of non-smokers only would not 
be representative of most clinical populations with psychotic disorders and I 
included participants regardless of their smoking habit. My patient and control 
groups were not significantly different in smoking status; hence smoking is 
unlikely to have confounded my results. Nevertheless, all my analyses were 
adjusted for tobacco smoking in this sample. 
One potential limitation of my study is that the regions of interest (ROIs) were 
manually drawn directly on the SPECT image. Whilst there is the potential for 
observer bias using this approach, I minimised this risk by ensuring that the ROIs 
were delineated by an experienced nuclear-medicine physician independent of the 
clinical assessment and blind to the subject’s clinical group. We delineated the 
ROI on the SPECT image rather than on the MRI image as this does not require 
the ROI to be transformed from MRI to SPECT space. However, studies have 
found similar results using both approaches (Wang et al., 1996; Inoue et al., 2004) 
indicating that the choice of approach is unlikely to have influenced our findings.  
Another potential limitation is that patients recruited in my study for SPECT 
imaging had to be cooperative and relatively stable in order to complete the 
procedure. This is an issue for most imaging studies and may potentially affect 





(4.3)    Interpretation of Thesis Findings  
 
(i)    DAT Availability  
The pre-synaptic DAT plays a key role in regulating the dopamine (DA) 
content in the synaptic cleft by transporting it back into DA terminals, effectively 
modulating the concentration of DA available for postsynaptic receptor binding 
(Bannon et al., 2001). There are two main interpretations of my findings: on the 
one hand, if DA was able to displace [99mTc]-TRODAT-1 from DAT, my failure 
to find a difference in specific binding could be due to elevated synaptic DA 
levels in schizophrenia masking an increase in DAT levels (Abi-Dargham et al., 
2000). However, whilst the definitive studies have not yet been conducted, the 
available evidence indicates that [99mTc]-TRODAT-1 binding is not sensitive to 
variations in DA levels seen in vivo (Fernagut et al.). A more likely interpretation 
is thus that DAT levels are unaltered in schizophrenia. This is important as it 
indicates that there is no compensatory increase in DAT levels in response to the 
increased release and synaptic levels of DA previously reported in schizophrenia 
(Laruelle et al., 1999; Abi-Dargham et al., 2000). This interpretation is consistent 
with evidence that fluctuations in brain DA levels do not alter the abundance of 
the DAT (Moody et al., 1996). My findings might thus suggest pharmacological 
augmentation of DAT as a potential novel treatment strategy for schizophrenia.  
I identified a sex effect in the combined sample whereby females had a higher 
specific striatal radiotracer binding ratio than males, which is consistent with a 
previous study (Kuikka et al., 1997). The effect size for sex in my study is 0.25 
(Cohen’s d) and although this is a small effect, it might be of relevance. It would 
seem to be in line with the later age of onset and lower incidence of schizophrenia 
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in females (Faraone et al., 1994). The lower DAT availability in males could 
contribute to their earlier age of onset as, putatively, they would have less 
capacity to buffer excess striatal DA release. 
My finding that there is a negative relationship between age and DAT 
availability is consistent with a previous study showing that the specific uptake of 
[99mTc]-TRODAT-1 radiotracer decreases with advancing age in healthy 
individuals (Mozley et al., 1999). Since the density of striatal DA D2/D3 receptors 
also declines with age in healthy individuals (Chen et al., 2005), my data indicate  
the consistency of this age effect on both pre- and post-synaptic dopaminergic 
function.  
The PANSS scores for positive and negative symptoms of schizophrenia and 
general psychopathology did not correlate with the [99mTc]-TRODAT-1 binding 
ratio. This is again consistent with previous research (Hsiao et al., 2003; Yang et 
al., 2004; Schmitt et al., 2005) and with the absence of alterations in [99mTc]-
TRODAT-1 availability in my patients as a group.  
The meta-analysis including my data found there was no evidence for a 
difference in striatal [99mTc]-TRODAT-1 binding in drug-naïve patients with 
schizophrenia compared to controls. Considering the range of effect sizes 
included in the 95% confidence interval, the standardized effect size is unlikely to 
exceed 0.31, which is conventionally considered to be a small effect (Cohen, 
1988). With this effect size, as many as 188 drug-naive patients and an equal 
number of controls would need to be tested to have 85% power to detect a 
difference (two-group T test with a 5% two sided significance level). The overall 
conclusion of my work is that drug-naïve patients in the early stages of 
schizophrenia have normal [99mTc]-TRODAT-1 binding and that any impairments, 
if present, would be of a small magnitude. Given the normal variation in binding, 
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any potential deficits in drug-naive patients are unlikely to be clinically 
significant. Although [99mTc]-TRODAT-1 binds to serotonin transporters, 
blocking studies show that the specific binding in the striatum is almost entirely 
due to dopamine transporters (Dresel et al., 1999), hence, my findings reflect that 
DAT availability is unaltered in drug-naïve patients with schizophrenia.   
 
(ii)    P300 ERP 
I suggest that our failure to find P300 amplitude or latency differences 
between drug naïve patients and normal controls might be related to the relatively 
short duration of psychotic illness of my patients. Indeed, previous studies have 
identified a correlation whereby the P300 amplitude was more reduced and 
latency was more delayed with longer illness duration (Mathalon et al., 2000b). 
The P300 ERP involves the complex summation of activity from multiple brain 
regions, particularly the various association areas of the cerebral cortex and the 
limbic system (Picton, 1992; Bledowski et al., 2004; Polich, 2007; Mangalathu-
Arumana et al., 2012), which in turn are thought to originate from deeper brain 
sources such as the striatum (Kellendonk et al., 2006; Howes & Kapur, 2009). 
The lack of correlation between P300 performance and striatal DAT availability 
in this study is in line with my previous findings that DAT availability is not 
impaired in drug naïve patients with schizophrenia (Chen et al., 2013) and with 
the progressive brain pathophysiological process correlating with duration of 
illness as mentioned above (Mathalon et al., 2000b).  
There was also a significant sex effect in my combined sample, whereby the 
P300 amplitude was lower in males compared to females, as reported in a 
previous study on healthy individuals (Schiff et al., 2008). This is consistent with 
 62 
the later age of onset and lower incidence of schizophrenia in females (Faraone et 
al., 1994).  
Previous studies have reported that the unaffected relatives of patients and 
other populations at risk for psychosis have similar, yet milder P300 amplitude 
and latency deficits, suggesting that the P300 amplitude reductions and latency 
delays may be conceptualized as biomarkers of genetic predisposition to 
psychosis (van Beijsterveldt, 2002; Bramon et al., 2005; Bramon et al., 2008). 
My data challenge this notion and indicate that the P300 could rather be a marker 
of disease chronicity/progression. 
Some studies have shown P300 amplitude reduction in populations of ultra 
high risk (UHR) for psychosis (Yung et al., 2005) either prior to the onset of 
psychosis compared to controls (Bramon et al., 2008; Frommann et al., 2008) or 
after transition to psychosis compared to the state before transition (van Tricht et 
al., 2010). However, the basis of their vulnerability to psychosis is not fully 
understood (Fusar-Poli et al., 2013a; Fusar-Poli et al., 2013c). Hence, compared 
to patients with established schizophrenia, such high risk individuals could have a 
different underlying pathophysiology that is distinct from a genetic vulnerability 
to schizophrenia. It is also possible that some ERP components, such as P300 
amplitude abnormalities could be present before a psychotic episode but do not 
show further progression immediately following the psychotic onset (van Tricht 
et al., 2011). Therefore, my data suggest the P300 could rather be a marker of 
disease chronicity/progression in patients with schizophrenia but not in the UHR 
population. Nevertheless, the discrepancy between my data and results from UHR 
population ERP studies clearly needs further exploration. 
The role of psychotropic medication on evoked potentials is controversial. 
P300 amplitude and latency in patients with schizophrenia may tend to normalize 
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after pharmacological intervention (Coburn et al., 1998; Gonul et al., 2003), 
however, the absence of such drug effects has also been reported (de Wilde et al., 
2008). Several studies conducted on un-medicated patients who were not drug 
naive suggest that they also show amplitude reductions and latency delays 
(Bramon et al., 2004b). My findings of normal P300 performance in medication 
naïve patients would support an enduring confounding effect of medication, 
however longitudinal studies before and after introducing medication are required 
to clarify this matter.  
The meta-analysis including my data found that, drug-naive patients with 
schizophrenia do not have significant impairments in P300 latency compared with 
controls. Considering the pooled effect size of -0.13 and the range of effect sizes 
included in the 95% CI, the standardized effect size is unlikely to exceed -0.37, 
which is conventionally considered to be a moderate effect (Cohen, 1988). 
Therefore, my data and the meta-analysis of the literature show quite 
convincingly that in medication naïve patients the P300 latency is unlikely to be 
impaired.  
The meta-analysis of P300 amplitude yielded a much larger pooled 
standardized effect size of 0.48 with a trend for significance (Cohen, 1988). 
Considering all the evidence, I am inclined to conclude there probably are no 
clinically relevant impairments in amplitude in drug naïve patients in the early 
stages of the illness. I excluded studies of drug-free previously treated patients 
which were reported as showing P300 differences between patients and controls; 
hence their inclusion may have changed the outcome of my meta-analysis. 
Unfortunately there were too few studies eligible for inclusion for me to examine 
publication bias and heterogeneity in a meaningful way. 
 64 
I found a significant age by group interaction on P300 latency in my data, 
whereby the patients showed greater latency delays with ageing; thus the 
difference between patients and controls in P300 latency became more 
pronounced with increasing age (Gilmore, 1995; O'Donnell et al., 1995; Wang et 
al., 2003; Araki et al., 2006). This finding is not surprising and could reflect a 
faster age-related decline in the speed of neural transmission amongst patients 
with schizophrenia.  
A potential limitation is that patients recruited into my study had to be 
relatively stable and well enough to complete an extensive battery of clinical, 
cognitive, EEG and neuroimaging tests, which may potentially reduce the 
generalizability of my findings to a wider population including more severely ill 
and/or less cooperative patients. Furthermore, a study of non-smokers only would 
not be representative of most clinical populations, and I included participants 
regardless of their smoking habit. My patient and control groups were not 
significantly different in smoking status; hence, smoking is unlikely to have 
confounded my results. My controls were recruited from the local community 
through research advertisements and, compared to the patients, they were 
significantly older, had spent more time in education and were more likely to live 
with a partner; these demographic differences being comparable to previous 
studies (Loughland et al., 2010). Family studies suggest that the unaffected and 
thus un-medicated relatives of patients may show similar if milder deficits in the 
P300 as schizophrenia patients. Since my controls were not screened against 
having a family history of psychosis, this might potentially confound results and 
contribute to a lesser difference between patient and control groups. Finally it 
should be noted that I statistically adjusted all my analyses by age and sex, thus 
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all things considered, I believe that my controls provided a suitable comparison 
group. 
 
(4.4)   Alternative Explanations for our Negative Findings 
 
As described in the introduction, several studies have reported that the 
unaffected relatives of patients and other populations at increased risk for 
psychosis (such as people with sub-clinical psychotic experiences) have similar, 
yet milder P300 amplitude and latency deficits (Yung et al., 2005; Bramon et al., 
2008; Frommann et al., 2008; van Tricht et al., 2010). This body of research 
suggests that the P300 amplitude reductions and latency delays are biomarkers of 
genetic predisposition to psychosis (van Beijsterveldt, 2002; Bramon et al., 2005; 
Bramon et al., 2008). A recent study claims that P300 performance can improve 
the accuracy of clinical assessments aiming to identifying those “at risk” 
individuals who go on to develop a full blown psychotic episode (Nieman et al., 
2014). My results however challenge this notion and indicate that the P300 may 
in fact be a marker of disease progression and chronicity. 
Typically these “at risk” populations have undergone EEG testing prior to 
starting any antipsychotic treatment and medication confounding is highly 
unlikely to be a problem. However, these “at risk” samples tend to be particularly 
heterogeneous and their vulnerability to psychosis can have multiple and diverse 
origins that remain poorly understood (Fusar-Poli et al., 2013a; Fusar-Poli et al., 
2013c). A minority of people with “prodromal” or “at risk” mental states have a 
known family history of psychosis. The majority of these populations actually 
have no identified genetic risk factors but do display a wide range of mild or 
short-lived psychotic experiences.  
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A further caveat to highlight is that the “ultra-high risk/prodromal” studies 
tend to undertake EEG at baseline and then follow up participants for one or 2 
years after disease onset. To establish if P300 deficits are markers of disease 
progression and chronicity we will need to cover substantially longer periods of 
follow up and most importantly need to undertake the baseline as well as new 
follow up EEG recordings after illness onset. Such studies are complex and have 
not yet been done in the psychosis field.  
A final and crucial alternative explanation is related to statistical power 
limitations of my sample. As described in chapter 3 of this thesis, I conducted a 
meta-analysis including both my data as well as the few existing comparable 
studies in drug-naïve patients. I found that, drug-naïve patients with schizophrenia 
do not have significant impairments in P300 latency compared with controls. 
From my meta-analysis I would argue that the standardized effect size is unlikely 
to exceed -0.37, which is conventionally considered a moderate effect (Cohen, 
1988). Given this moderate effect size, my sample of 36 patients and 138 controls, 
would have only 60%  power to detect a difference in latency (ES=0.4, two-group 
T test with a 5% two-sided significance level would yield about 60% power). 
Although my data and the meta-analysis of the literature show that in medication 
naïve patients the P300 latency is not impaired, the possibility of a type II error 
needs to be considered.  
The meta-analysis of P300 amplitude yielded a much larger pooled 
standardized effect size of 0.48 with a trend for significance and a potentially 
large effect size according to the 95% confidence interval (Cohen, 1988). 
Therefore, my sample of 36 patients and 138 controls had at least 72% power to 
detect this larger effect size. However the P300 amplitude literature showed 
evidence of publication bias and as a result the meta-analysis could over-estimate 
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the strength of the effect. Although unlikely, again a type II error for amplitude 
needs to be considered as an alternative explanation.   
Given the power estimations given above, it is conceivable that drug naïve 
patients with psychosis may have true impairments in P300 amplitude and latency 
that were missed both by my study and by the limited existing literature in this 
particular patient group. This alternative explanation would also be consistent 
with those studies that have identified P300 impairments in pre-psychotic at-risk 
populations and that view the P300 as a trait marker of disease vulnerability 
(Bramon et al., 2005; Bramon et al., 2008).  
 
The evidence that P300 changes with illness duration 
 
Several studies conducted with patients with schizophrenia have shown that 
the P300 amplitude and latency performance declines (smaller amplitude; longer 
latency) with a longer duration of illness and that this effect is not simply 
explained by normal ageing. Indeed the P300 amplitude was inversely correlated 
with illness duration (Olichney et al., 1998). Similarly P300 latency prolongation 
in schizophrenic patients with longer illness durations has also been reported 
(O'Donnell et al., 1995; Frangou et al., 1997; Olichney et al., 1998). According to 
Mathalon the P300 amplitude was more reduced and latency was more delayed 
with longer illness duration in patients with schizophrenia (Mathalon et al., 
2000b). Among patients with schizophrenia, P300 amplitude correlated positively 
with age of onset and negatively with illness duration. P300 latency correlated 
positively with age in patients with schizophrenia and also tended to increase with 
age in controls. However, the slopes of the latency-age relationships were 
significantly greater in patients with schizophrenia than in controls indicating a 
faster decline with ageing amongst patients. Finally, the P300 latency correlated 
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positively with illness duration but showed no relationship to age of onset 
(O'Donnell et al., 1995; Frangou et al., 1997). These studies support my 
hypothesis that the P300 deficits are markers of disease progression.  
 
Conclusions on the interpretation of the P300 findings 
 
In conclusion, the lack of clear differences between the first episode drug 
naïve cases and controls in the current study could indicate that:  
(a) much of the research literature on P300 and schizophrenia is confounded by 
antipsychotic medication, and/or the effect of illness on P300 is much less than 
commonly supposed and hence less readily detected in small samples; and  
(b) the P300 may be considered a marker of disease progression/chronicity. 
However, the discrepancy between these findings and results from ultra-high risk 
population ERP studies clearly needs further exploration and it is not possible to 
resolve the issue here. It is plausible that the P300 deficits described might be a 
non-specific marker of predisposition of some individuals to psychosis (hence the 
ultra-high risk and family study findings) as well as a marker of disease 
progression. Indeed some research supports the notion of the P300 being both a 
trait and state marker (Turetsky et al., 1998a; Turetsky et al., 1998b; Turetsky et 
al., 2000).  
According to Mathalon, the P300 amplitude reduction reflects not only a trait-
marker characteristic of schizophrenia, but can also fluctuate with clinical state 
(Mathalon et al., 2000b). Reduced P300 amplitude was found in patients whose 
symptoms had been improved or largely remitted with medication use 
(Blackwood et al., 1987; Coburn et al., 1998; Mathalon et al., 2000a; Pass et al., 
1980; St Clair et al., 1989; Rao et al., 1995; Turetsky et al., 1998a). Reduced 
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P300 amplitude has also been reported in first-episode patients (Hirayasu et al., 
1998; Salisbury et al., 1998) as well as in unaffected first-degree relatives of 
schizophrenia (Blackwood et al., 1991; Kidogami et al., 1991; Roxborough et al., 
1993; Frangou et al., 1997).  
Moreover, other studies also implicate P300 amplitude as a clinical-state 
marker in schizophrenia by showing associations with clinical symptoms 
(Pfefferbaum et al., 1989; Eikmeier et al., 1992; Egan et al., 1994; Maeda et al., 
1996; Turetsky et al., 1998b; Ford et al., 1999; Mathalon et al., 2000a) as well as 
showing sensitivity to clinical-state fluctuations over time (Maeda et al., 1996; 
Turetsky et al., 1998a; Mathalon et al., 2000a) and to medication effects 
independent of clinical state (Coburn et al., 1998; Umbricht et al., 1998). Thus, as 
a marker of both state and trait, P300 amplitude is particularly suitable for 
tracking progressive neuropathological processes over the long-term illness 
course.  
Finally, an important limitation of the current P300 literature in schizophrenia 
including the current study as well as my meta-analysis is that virtually all 
published studies are cross-sectional investigations of independent samples at 
different levels of risk and at different disease and treatment stages. As a result, 
reconciling such a heterogeneous body of cross-sectional work is very 
challenging. Longitudinal cohort studies investigating EEG markers from the 
prodrome and re-testing participants over several years after disease onset are 
needed. This would be the ultimate way to establish if the P300 is a trait marker 
of vulnerability, a marker of disease progression or a combination of both. 
Although the data I have presented in my thesis are the baseline assessments of 
my participants at the point of recruitment, my colleagues and I at Tainan’s 
University Hospital have continued to follow up these patients over several years. 
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We hope to soon complete a longitudinal 5-year follow up study including a 
range of neuroimaging and biological testing of this cohort of patients.  
 
(4.5)    Conclusions and Future directions 
 
My DAT availability findings, in the largest first-episode drug-naïve and 
healthy sample studied to date, suggest that striatal DAT availability is not altered 
in the early stages of schizophrenia before medication is introduced. Instead, I 
identified sex differences and confirmed ageing effects that could have clinical 
significance and may be taken into account in future studies.  
Furthermore, my P300 findings also suggest that the P300 ERP is not altered 
in the early stages of schizophrenia before medication is introduced, and the DAT 
availability does not influence the P300 ERP amplitude or latency. The P300 ERP 
could be an indicator of the progression of illness and chronicity. I also identified 
sex differences and aging effects as DAT availability findings that could have 
clinical significance and may be taken into account in future studies. As there are 
only 4 P300 studies of drug naïve patients with schizophrenia and all of them are 
cross sectional, further longitudinal studies which explore the effect of medication 
and duration of illness upon the P300 ERP are needed.       
The importance of taking into account medication effects is emphasized by this 
thesis as is the value of converging methodologies such as research on families and 
other ‘at risk’ populations and longitudinal cohort studies.  
In future, there are other endophenotypes for psychosis that I would like to 
investigate in my sample of drug naïve patients with schizophrenia. These include 
EEG markers like the mismatch negativity (MMN), which is a pre-attentive 
measure of auditory processing well characterized in psychosis (Bramon et al., 
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2004a; Umbricht & Krljes, 2005). Another interesting endophenotype is the P50 
waveform, which tackles brain gating mechanisms that are impaired in psychosis 
and could be useful endophenotypes for genetic research (Shaikh et al., 2015). 
Magnetic Resonance Imaging (MRI) also offers a promising method to identify 
putative endphenotypes for psychotic disorders (McDonald et al., 2004; Arnone et 
al., 2009; van Erp et al., 2015). 
In a previous paper, we described how striatal dopamine D2/3 receptor 
availability, as measured by SPECT ligand [123I] iodobenzamide (IBZM), was 
associated with schizotypal traits in healthy people (Chen et al., 2012). Therefore 
we conducted a similar IBZM experiment with my drug naïve patient sample and 
this is the focus of another ongoing manuscript currently in preparation.  
Further longitudinal follow up of the drug naïve patients participating in my 
research has already been initiated. These patients have agreed to attend regular 
post-treatment assessments, which might help us to answer the questions raised by 
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APPENDIX 1  
 
FURTHER DEMOGRAPHIC DATA 
 
 
In chapters 2 and 3 of the thesis (published papers) only basic demographics 
were provided. Here we have included additional information on family history, 
age of onset/duration of illness and detailed psychopathology data. Although 
obstetric complications are a well-known risk factor for schizophrenia and other 
psychotic disorders (Cannon et al., 2002), in our cohort we had no access to 
reliable information on birth history.  
 
Patients and controls had a similar sex and tobacco smoking status 
distribution. However, compared with the controls, the patients were 
significantly younger, less likely to be married, and had fewer years of 
education. Of the 47 patients included in the DAT study, 43 completed the GAF, 
42 the PANSS, and 39 the CGI scales (Table A). Of the 36 patients included in 





















Table A. Detailed Demographic Characteristics of the Participants in chapter 




(n = 47) 
Controls 
(n = 112) 
Statistics 
Mean (SD) Mean (SD) t /χ2 df p 






-4.19 117.7 <0.001 
Sex (male/female)  26/21 59/53 0.09 1 0.761 
Smoking status (yes/no) 5/42 19/93 1.03 1 0.300 
Marital status(M/S)§   5/42 42/70 11.47 1 0.001 






-2.62 154 0.010 
Age of onset 
   range 
23.5 (7.4) 
14-44 
NA NA NA NA 
Family history of 
psychiatric illness (%) 
14/33 NA NA NA NA 
Alcohol use (Y/N) 1/44 5/107 0.44 1 0.51 
Suicide attempt (Y/N) 3/44 NA NA NA NA 

















NA NA NA NA 








NA NA NA NA 
§:  M, includes married and living with a partner.  S, includes single, divorced, 
married but separated. 
PANSS: Positive and negative syndrome scale 
CGI: Clinical global impression 


























Table B. Detailed Demographic Characteristics of the Participants in chapter 
3 (P300 study) 
 
Schizophrenia 
(n = 36) 
Controls 
(n = 138) 
Statistics 







4.56 95.42 <0.001 
Sex (male/female) 21/15 74/64 0.26 1 0.61 
Smoking (yes/no) 3/29 25/109 1.59 1 0.21 
Marital Status (M/S)a 3/33 42/95 7.38 1 0.007 






3.32 171 0.001 
Age of onset 
   range 
23.3 (5.8) 
15-39 
NA NA NA NA 
Family history of 
psychiatric illness (%) 
9/27 NA NA NA NA 
Alcohol use (Y/N) 2/34 6/130 0.08 1 0.77 
Suicide attempt (Y/N) 1/32 NA NA NA NA 












NA NA NA NA 
Total PANSS 76.9 (23.0) NA NA NA NA 
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32-143 








NA NA NA NA 
a: M, includes married and living with the partner. S, includes single, divorced, 
married but separated.  
PANSS: Positive and negative syndrome scale 
CGI: Clinical global impression 


























APPENDIX 2  
 
THE INFLUENCE OF AGE ON RECEPTOR BINDING AND P300 AND A 
COMPARISON BETWEEN THE TWO 
 
The main aim of my study was to assess the differences between patients and 
controls in the specific striatal [99mTc]-TRODAT-1 binding, considering both the 
left and right striatum measures. Mixed modeling was used to compare [99mTc]-
TRODAT-1 binding between the 2 clinical groups, and to allow for possible 
group differences between left and right sites, we tested if a group by laterality 
interaction was evident.  
 
On the basis of previous literature, we considered that age, sex, and tobacco 
smoking are potential confounders and therefore included these as covariates in 
the analysis (Kuikka et al., 1997; Mozley et al., 1999; Newberg et al., 2007). The 
models included subject-varying intercepts to acknowledge correlation between 
the 2 repeated measures per participant.  
 
The second aim of this study was to evaluate the effects of aging, sex, and 
tobacco smoking on the specific striatal [99mTc]-TRODAT-1 binding, and we 
present the regression coefficients obtained from the model described above. My 
third and final objective was to use the data to assess if any group effect varies 
with age or sex. Thus, we expanded the above model to test an interaction of 
group by age or group by sex, respectively. 
 
Here I list the detailed results of statistical analyses using SPSS version16 
(SPSS Inc., Chicago, IL, USA). Key results are highlighted in yellow. 
 
Additional statistical analyses on TRODAT binding 
 
The group by laterality interaction was not significant and was therefore 
dropped from our model (F = 2.02, df = 1, 157; P = 0.16).  
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After controlling for age, sex, and tobacco smoking, the mean specific 
striatal binding showed a trend for a difference between patients and controls, 
where patients had a reduction in their TRODAT binding (estimated difference 
between controls and patients = 0.071; 95% CI 0.01, 0.15; F = 3.19, df = 1, 154; P 
= 0.08). Please see Tables A & B. 
In the same model, there was a significant effect of sex, whereby females 
had a higher ratio of the specific striatal binding than males (estimated difference 
between males and females = 0.08; 95% CI 0.15, 0.002; F = 4.11, df = 1, 154; P = 
0.045). Please see Table C. 
Tobacco smoking did not have a significant influence on TRODAT binding 
(estimated difference between smokers and nonsmokers = 0.06; 95% CI 0.17, 
0.04; F = 1.39, df = 1, 154; P= 0.24), please see Table C. Finally, there was a 
highly significant effect of age, whereby TRODAT binding declined with 
advancing age (estimated change per decade of age = 0.1; 95% CI 1.2, 0.6; F = 










B Std. Error 
1 (Constant) 2.562 .064 
age -.009 .002 
























1 (Constant)  39.891 .000 2.436 2.689 
age -.432 -5.644 .000 -0.0122 -0.0059 
sex -.161 -2.023 .045 -0.1538 -0.0018 
tobacco 
use 
-.094 -1.181 .239 -0.1678 0.0422 







Tests of Between-Subjects Effects 
Dependent Variable: TRODAT binding availability  
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Corrected 
Model 
1.758a 4 .440 9.118 <.001 
Intercept 91.055 1 91.055 1888.722 <.001 
age 1.536 1 1.536 31.855 <.001 
group .153 1 .153 3.182 .076 
sex .197 1 .197 4.092 .045 
tobacco use .067 1 .067 1.394 .239 
Error 7.424 154 .048   




   





Of note, there was no significant interaction between age and group (F =0.37, 
df = 1, 153; P = .55), please see Table D, or between group and sex (F = 0.20, df 
= 1, 153; P = .66), please see Table E, indicating that the age decline in TRODAT 
was similar in patients and controls as well as in both sexes. Finally, again no 
significant interaction between age and sex was found on the DAT binding, 









Tests of Between-Subjects Effects 
Dependent Variable: TRODAT binding availability 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Corrected 
Model 
1.776a 5 .355 7.338 <.001 
Intercept 64.139 1 64.139 1324.956 <.001 
age .763 1 .763 15.762 <.001 
group .063 1 .063 1.297 .257 
sex .203 1 .203 4.200 .042 
tobacco use .076 1 .076 1.565 .213 
group * age .018 1 .018 .368 .545 
Error 7.407 153 .048   




   



















Tests of Between-Subjects Effects 
Dependent Variable: TRODAT binding availability  
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Corrected 
Model 
1.768a 5 .354 7.296 <.001 
Intercept 89.648 1 89.648 1849.823 <.001 
age 1.539 1 1.539 31.759 <.001 
group .160 1 .160 3.310 .071 
sex .148 1 .148 3.056 .082 
tobacco use .062 1 .062 1.284 .259 
group * sex .010 1 .010 .197 .658 
Error 7.415 153 .048   




   



















Tests of Between-Subjects Effects 
Dependent Variable: TRODAT binding availability 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Corrected 
Model 
1.773a 5 .355 7.323 <.001 
Intercept 90.725 1 90.725 1873.392 <.001 
age 1.550 1 1.550 32.011 <.001 
group .145 1 .145 3.000 .085 
sex .002 1 .002 .045 .832 
Tobacco use .065 1 .065 1.343 .248 
sex * age .015 1 .015 .307 .580 
Error 7.409 153 .048   




   




Additional statistical analyses on P300 amplitude and P300 latency 
performance 
Based on equivalent statistical analyses used in the DAT binding section 
above, no significant interactions between age and sex were found on the P300 
amplitude and latency. In Appendix 4 below, we have undertaken additional 
analyses examining the effects of age and sex on P300 performance. This 
includes a re-analysis of a sub-sample of patients and controls that were well 
matched demographically. Finally further analyses are presented on the full 
patient and control sample that compare the P300 models with and without 
adjustment by sex and age (Appendix 4).  
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In conclusion and consistently with the literature, TRODAT binding declined 
with age in my sample. This effect was observed both in patients and in controls, 
and in both sexes. Again in my study we found the expected ageing effects on 







METHODOLOGICAL CONSIDERATIONS – INCLUSION OF CORRECT
TRIALS IN THE AVERAGING OF EEG SIGNALS 
 
The P300 event related potential is typically measured from an average of 
multiple single trials. The amplitude reductions described amongst patients with 
schizophrenia are observable even after trials with no visible P300 waveform are 
excluded and when trials are latency adjusted (Ford et al., 1994a).  
 
In the extensive literature investigating the P300 waveform in schizophrenia, 
the classical approach has been to average trials containing standard and target 
stimuli separately and to only include in the averages those trials eliciting correct 
responses from the participant (no response to standard tones and button-press or 
other response to targets) (Ford et al., 1994a). Thus, in order to measure the P300 
amplitude and latency the majority of studies have averaged only the artefact-free, 
correctly identified target trials (Ford et al., 1994a; Frangou et al., 1997; Bramon 
et al., 2005; Bramon et al., 2008). The paradigm we selected for my sample was a 
two-tone oddball and in all respects was comparable to these studies mentioned. 
Accordingly, we decided to undertake a similar analysis based on averaging only 
the correctly identified target trials. Furthermore, it is the correct identification of 
the target tones that is thought to generate the P300 waveform (Ford et al., 1994a; 
Falkenstein et al., 1997). The rationale for taking this approach is to maximise 
data quality and facilitate interpretation. If EEG epochs generated during missed 
targets were to be averaged together with correctly identified targets, a number of 
confounding effects on the underlying cognitive process might arise and 
interpretation would be more difficult (Ford et al., 1994a; Frangou et al., 1997).  
 
Nevertheless, the design of my oddball experiment, just as was the case in 
many several preceding studies (Frangou et al., 1997; Bramon et al., 2005; 
Bramon et al., 2008), involved the use of an easy task. The target and standard 
tones had frequencies of 2000 and 1000 Hz respectively. This large difference in 
pitch made it very easy for all study participants including patients with 
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schizophrenia to identify the targets. Given the easy nature of the oddball task in 
my study, the number of missed targets was very small and their inclusion would 
have been unlikely to influence the P300 amplitude and latency calculations in 
any event.  
 
Table A gives details on the performance to my oddball task at a behavioural 
level. The accuracy of patients and controls is similar and very high. The patients 
and controls were able to correctly identify 99% of targets. Thus, including the 
targets that participants failed to correctly respond to, would result in adding only 
another 2 trials per subject on average and this would be unlikely to have a 
significant influence on the P300 waveforms we obtained. P300 oddball tasks 
have traditionally been designed to be relatively easy in order to ensure a 
sufficient number of correctly identified trials can be included in the averages for 
most participants thus maximising data quality.  
 
 
Table A: Group comparisons on behavioural accuracy to the oddball task 
 
 
This experiment consisted of 200 tones (80% standards and 20% targets). The 
subject was instructed to respond to the targets only. Using independent samples 
 Controls Patients Statistics 
(independent samples 
T test) 
Sample size N=135 N=35  
% of total correct responses  
Mean (±SD) 
99.2 (2.1) 98.6 (4.2) p=0.24  
 
Sample size N=129 N=29  
% of correctly identified targets  
Mean (±SD) 
96.1 (11.7) 95.4 (11.9) p=0.71 
% of correctly identified 
standards 
Mean (±SD) 
99.9 (0.4) 99.7 (0.9) p=0.22 
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T test, there was no significant difference in accuracy of behavioural response to 
the oddball task between the two groups.   
 
 
METHODOLOGICAL CONSIDERATIONS – JUSTIFICATION OF SITES
SELECTED FOR INVESTIGATION 
 
The majority of papers in the schizophrenia P300 literature have investigated 
midline electrodes (Frangou et al., 1997; Jeon & Polich, 2001; Bramon et al., 
2004a; Bramon et al., 2005; Polich, 2007; Bramon et al., 2008). The P300 signal 
is strongest and most reliably measured in central parietal areas. This is the reason 
most research in the field reports on the PZ and the CZ sites. The scalp 
distribution of the P300 signal typically shows amplitude increases from frontal to 
parietal electrode sites (Johnson, 1993).  
 
However, as in other auditory tasks, temporal areas are also likely to be 
relevant. Indeed, P300 differences between patients with schizophrenia and 
controls have also been described in temporal areas bilaterally (Jeon & Polich, 
2001; Kim et al., 2014). Asymmetries have been described in schizophrenia in 
laterality comparisons (McCarley et al., 1993; McCarley et al., 2002).  
 
In my study, the EEG was acquired over 32 electrodes using the 10/20 
international system (Jasper, 1958). However, for the P300 experiment only three 
midline electrodes FZ, CZ and PZ were analysed. Although it would certainly 
have been possible to analyse many alternative sites, given that our sample 
included 36 patients and 138 controls, some form of data reduction was needed. I 
considered the option of undertaking a factor analysis of all 32 sites in order to 
extract 2 or 3 key components from each individual for subsequent analysis. 
However this approach is rarely used in the P300 schizophrenia literature and this 
would make putting my findings into context potentially difficult. In the end, I 
opted for focusing on the three midline electrodes because this approach has been 
most commonly used in the P300 schizophrenia literature and would allow a 






THE DEMOGRAPHIC MATCHING OF PATIENTS AND CONTROLS IN 
THIS STUDY 
 
In my study, the patients and controls had significant differences in age 
distribution. The sex distribution was however balanced with no significant group 
differences (table 1 of Chapter 3). Indeed, the age range of the control and the 
patient groups was respectively 19-58 and 18-39 years, and the mean age was 
significantly younger amongst patients compared to controls. Even though all my 
analyses are adjusted for age, the inclusion of older controls could have affected 
my results. A well-established effect of ageing is to increase the latency and to a 
lesser extent to reduce the amplitude of the P300 (Polich et al., 1985; Jeon & 
Polich, 2001). Therefore, it is conceivable that with age matched patients and 
controls I might have found P300 amplitude and latency group differences as 
previous studies have done (Wang et al., 2003). In my thesis I opted to include all 
my study participants (36 patients and 138 controls), despite the age group 
imbalances, in order to maximise statistical power.  
 
Nevertheless, I have now conducted further analyses with a subgroup of 
randomly-selected 30 patients and 30 controls individually matched by age and 
sex (Table A). No difference between groups was found in P300 amplitude or 
latency in the matched sub-sample (Table A and Table B). I acknowledge that by 






Table A. Demographic characteristics of patients with schizophrenia (n = 30) and 
age and sex matched controls (n = 30) 
  
 
Patients Controls Statistical test 







-0.02 58 0.98 
Sex (male/female) 15/15 15/15 - - - 
Smoking (yes/no) 2/24 6/24 1.72 1 0.19 
Marital Status (M/S)a 3/27 4/26 0.16 1 0.69 






-1.76 58 0.08 








1.89 44 0.07 
Duration of illness (months) 
  range 
40.2 (72.3) 
1.0-288.8 
NA NA NA NA 
















NA NA NA NA 




NA NA NA NA 
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a: M, includes married and living with the partner. S, includes single, divorced, 
married but separated.  
b: The specific striatal [99mTc]-TRODAT-1 binding as the measure of dopamine 
transporter (DAT) availability was calculated via the mean count of regions of 
interest in the striatum divided by it in the occipital region (St/Oc).  
PANSS: Positive and negative syndrome scale 





Table B. Latency / amplitude of patients with schizophrenia (n = 30) and age and 
sex matched controls (n = 30) 
 
 Parietal Central Frontal 
Statistical 
analysis 
 Mean (SD) Mean (SD) Mean (SD) coefficient p 
Latency (ms)         
Schizophrenia 339.93  (31.07) 336.07  (33.44) 336.87  (33.93) -5.70 0.48 
Normal control 332.97  (31.77) 331.57  (31.94) 331.17  (29.80)   
Amplitude (μV)         
Schizophrenia 7.94  (3.88) 7.61  (3.91) 6.32  (3.37) 0.77 0.40 
Normal control 9.10  (4.32) 7.99  (4.41) 7.07  (4.77)   
 
 
The findings prior to co-variation for age and sex and after co-variation for 









Table C: Latency/amplitude of patients with schizophrenia (n=36) & controls 
(n=138) 
 Parietal Central Frontal 
Statistical analysis 
Controlling for age, sex, 
and electrode site 
Controlling only for 
electrode site 
 Mean (SD) Mean (SD) Mean (SD) coefficient t p coefficient t p 
Latency 
(ms) 
            
Schizophrenia 338.9 (29.2) 335.0 (31.2) 335.7 (32.6) -3.85 -0.65 0.52 -5.02 0.88 0.38 
Normal 
control 
334.7 (32.5) 331.2 (32.8) 328.7 (33.8)       
Amplitude 
(μV) 
            
Schizophrenia 8.09 (4.20) 7.63 (4.00) 6.31 (3.32) 0.27 0.39 0.71 0.17 0.17 0.87 
Normal 
control 
8.00 (4.04) 7.32 (4.29) 7.08 (4.42)       
 
 
As per table C, prior to co-variation by age and sex there were no 
significant group differences between patients and controls in P300 
amplitude or latency. These results are similar to the age and sex adjusted 















APPENDIX 5  
 
A RE-ANALYSIS OF SYMPTOM CLUSTERS USING A FIVE-FACTOR 
MODEL OF THE PANSS IN MY PATIENT SAMPLE 
 
A five-factor model of the PANSS for the Chinese population 
 
The Positive and Negative Syndrome Scale (PANSS) is widely used to assess 
the severity of symptoms among patients with schizophrenia. A total of 30 items 
were designed to assess the severity of three a priori major symptom dimensions: 
A positive syndrome (7 items), a negative syndrome (7 items), and general 
psychopathology (16 items) (Kay et al., 1987). Subsequent studies have shown 
that the PANSS can measure five dimensions of symptomatology of 
schizophrenia. Wallwork et al. (2012) have built a consensus model by assigning 
only the consistent PANSS items to each of the five factors based on previously 
published models and advocate in favour of this five factor approach (Wallwork 
et al., 2012). However, few studies have ever investigated the structure of the 
PANSS in a Chinese schizophrenia population. A Chinese version the five-factor 
model of PANSS has been proposed which includes a positive, negative, 
excitement, depression and cognitive factors (Jiang et al., 2013). The items 
loaded on these factors were similar to the consensus items published in previous 
studies, except for PANSS items P2 conceptual disorganization, P5 grandiosity, 
N5 abstract thinking, and G11 poor attention. This discrepancy is thought to be 
due to the influence of culture on the clinical presentation of schizophrenia. Table 
A shows details of the validation study of the five-factor PANSS modelling for 











Table A. Validated five-factor model of the PANSS for schizophrenia in the 
Chinese population 
 
This table shows the factor loadings of the PANSS items and the number of 
models that have assigned the corresponding items to the corresponding factors in 




The relationship between the five-factor PANSS and DAT availability in 
my sample of antipsychotic naïve patients with schizophrenia 
 
I used the five-factor model of the PANSS, Chinese version from Jiang et al 
as the basis of my analyses in order to explore the associations between PANSS 
and DAT availability. The factor loadings of the PANSS items and the number of 
models that have assigned the corresponding items to the corresponding factors 
are showed in Table A. No significant association was found between striatal 
DAT availability and each of the five factors of the PANSS that we examined. 





Table B. Correlations between Striatal DAT availability and PANSS scores in my 
patient sample (n=42) using Jiang’s five-factor model 
 Positive Negative Excitement Depression Cognitive 
PANSS 
Mean (SD) 
12.51 (3.69) 11.06 (4.60) 5.65 (2.66) 4.06 (1.37) 2.98 (1.23) 




ρ 0.13 0.05 0.22 0.23 0.13 
p 0.41 0.78 0.16 0.14 0.40 
DAT: Dopamine transporter 
PANSS: Positive and negative syndrome scale 
ρ: Spearman’s Rho Correlation coefficients 
p: significance value of correlation analyses 
 
 
The relationship between the five-factor PANSS and P300 ERP in my 
sample of antipsychotic naïve patients with schizophrenia 
 
The P300 is a positive-going wave with a scalp amplitude distribution in 
which it is largest in parietal sites (Pz) and smallest frontally (Fz), taking 
intermediate values centrally (Cz). In a new analysis of our patient data, the P300 
amplitude was found to negatively correlate with the PANSS cognitive factor 
(disorientation, lack of judgement/insight) [mean (SD) =3.15 (1.83), Pz, ρ=-0.44, 
p=0.01] and with the PANSS positive factor (delusions, hallucinations, 











The P300 latency was found to positively correlate with the PANSS cognitive 
factor [mean(SD)= 3.15 (1.83), Pz, ρ=0.48, p=0.01], with the depression factor 
(anxiety, guilt feelings, depression) [mean(SD)= 4.70 (3.14), Pz, ρ=0.40, p=0.02], 
and finally with the excitement factor (hyperactivity, hostility, poor impulse 
control) [mean(SD)= 5.40 (2.27), Pz, ρ=0.40, p=0.04]. These analyses are fully 
reported in Table C.   
 
Patients with schizophrenia have P300 amplitude reductions and latency 
prolongations compared to healthy controls (Frangou et al., 1997; Coburn et al., 
1998; Ozgurdal et al., 2008; Shin et al., 2010; Jahshan et al., 2013). Even though 
the number of available studies is much smaller, antipsychotic free patients with 
schizophrenia have also been shown to have significantly attenuated amplitude 
and delayed latency on oddball paradigms eliciting the P300 response (Coburn et 
al., 1998; Bramon et al., 2004b). My results on the P300 amplitude are in line 
with the findings by Higashima et al, who reported that the score for the thought 
disorder factor of the PANSS correlated negatively with the amplitude of P300 in 
patients with schizophrenia (Higashima et al., 1998). My results are further 
supported by Kirihara et al., who also reported that the auditory P300 amplitude 
showed a significant negative correlation with two different measures of severity 
of thought disorder (Johnston & Holzman, 1979; Marengo et al., 1986). Thus the 
authors concluded that electrophysiological abnormalities of information 
processing may underlie the presence of thought disorder in schizophrenia 
(Kirihara et al., 2005).  
 
Moreover, P300 amplitude has been also implicated in other studies as a 
clinical-state marker in schizophrenia by showing associations with clinical 
symptoms (Pfefferbaum et al., 1989; Eikmeier et al., 1992; Egan et al., 1994; 
Maeda et al., 1996; Turetsky et al., 1998b; Ford et al., 1999; Mathalon et al., 
2000a). It tracked Brief Psychiatric Rating Scale (BPRS) total scores and positive 
symptom scores over time, with decreasing amplitude during symptom 
exacerbations (Mathalon et al., 2000a). Consistently with the above studies, in a 
study of males with recent onset psychosis, the P300 amplitude correlated with 
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symptom severity and could explain 66% of the patient’s performance in total 
PANSS scores (Sumich et al., 2006). Based on all these studies I would 
tentatively suggest that the P300 amplitude could be a physiological correlate of 
psychosis severity, especially reflecting degree of cognitive impairment and 
positive symptom severity. 
 
Again in my sample, the P300 latency positively correlates with the 
depression, excitement, and cognitive factors of the PANSS. These findings are 
also in line with the studies of major depressive disorder that previously reported 
P300 latencies were significantly prolonged both in major depressive patients 
with and without psychotic features compared to controls. Furthermore, P300 
amplitudes were significantly decreased only in the major depressive patients 
with psychotic features before treatment (Vandoolaeghe et al., 1998; Karaaslan et 
al., 2003).  
 
According to the aforementioned results (Appendix 1 Tables A & B, 
Appendix 5 Tables B & C), the symptomatology of patients recruited in my 
studies was not severe and this is reflected in their PANSS scores. This may have 
contributed to our failure to identify overall P300 differences between patients 
and controls in our study. However, there were significant associations between 
some symptom clusters, for example positive symptoms, cognitive and 
excitement factors. This suggests that a more symptomatic sample may indeed 
have given rise to a distinctive pattern of results for the patient group. Please note, 
these additional analyses are exploratory and statistical significance levels have 
not been adjusted for multiple comparisons. 




Table C. Correlations between P300 latency/amplitude and PANSS in my patient 
sample (n=33) using Jiang’s five-factor model 
 
 Positive Negative Excitement Depression Cognitive 
PANSS 
Mean (SD) 
12.96 (4.07) 10.43 (5.05) 5.40 (2.27) 4.70 (3.14) 3.15 (1.83) 
Range 3.01-27.10 4.19-29.32 2.36-10.99 2.06-18.57 1.23-11.11 
Latency (ms)      
Parietal  
ρ 0.30 0.22 0.37  0.40 0.480 
p 0.09 0.23 0.035 0.020 0.005 
Central 
ρ 0.29 0.09 0.33  0.40   0.35 
p 0.11 0.60 0.06 0.023 0.047 
Frontal 
ρ 0.23 -0.01 0.24  0.34   0.23 
p 0.20 0.98 0.18 0.053   0.20 
Amplitude (μV)      
Parietal  
ρ -0.32 -0.23 -0.05 -0.02 -0.44 
p  0.07  0.19  0.78  0.89 0.011 
Central 
ρ -0.39 -0.22 -0.25 -0.08 -0.50 
p 0.024  0.22  0.17  0.65 0.003 
Frontal 
ρ -0.33 -0.20 -0.35 -0.08 -0.51 
p  0.06  0.28 0.046  0.64 0.003 
PANSS: Positive and negative syndrome scale 
ρ: Spearman’s Rho Correlation coefficients 
p: significance value of correlation analyses 
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